Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none...

Full description

Saved in:
Bibliographic Details
Published in:JTO clinical and research reports 2022-01, Vol.3 (1), p.100260, Article 100260
Main Authors: Crowley, Fionnuala, Fitzgerald, Bailey G., Bhardwaj, Aarti S., Siraj, Irine, Smith, Cardinale
Format: Article
Language:English
Subjects:
Case Report
EGFR
Myositis
NSCLC
Osimertinib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c450t-1c061e0747440198d5b8ac4ba3b2209905f8f18c0dbe8972c055aff933a9476a3
cites cdi_FETCH-LOGICAL-c450t-1c061e0747440198d5b8ac4ba3b2209905f8f18c0dbe8972c055aff933a9476a3
container_end_page
container_issue 1
container_start_page 100260
container_title JTO clinical and research reports
container_volume 3
creator Crowley, Fionnuala
Fitzgerald, Bailey G.
Bhardwaj, Aarti S.
Siraj, Irine
Smith, Cardinale
description Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.
doi_str_mv 10.1016/j.jtocrr.2021.100260
format article
fullrecord <record><control><sourceid>elsevier_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3037aed886054078908381c3d5bc2233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666364321001193</els_id><doaj_id>oai_doaj_org_article_3037aed886054078908381c3d5bc2233</doaj_id><sourcerecordid>S2666364321001193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-1c061e0747440198d5b8ac4ba3b2209905f8f18c0dbe8972c055aff933a9476a3</originalsourceid><addsrcrecordid>eNp9kd1q3DAQhUVpaEKSNyhFL-Dt6NdyLwrF5A82TUlTArkRsizvyuxai6QE8vZV4jZNbnolMZrznRkdhD4SWBAg8vO4GHOwMS4oUFJKQCW8QwdUSlkxydn7V_d9dJzSCKVHEFIr-gHtMwEgpGAH6G7pB1fdrKMz2U1-WuHLx5B89gn7CRv8w2TvpoxvfV7jk7PT6-ryPpfWHn__2S5bHCZ8lfzWxewn333BrUkOX7tdiPkI7Q1mk9zxn_MQ_To9uWnPq-XV2UX7bVlZLiBXxIIkDmpecw6kUb3olLG8M6yjFJoGxKAGoiz0nVNNTS0IYYahYcw0vJaGHaKLmdsHM-pd9FsTH3UwXj8XQlxpU8azG6cZsNq4XikJgkOtGlBMEcuKp6WUscL6OrN2993W9basHs3mDfTty-TXehUetKqJ4o0oAD4DbAwpRTe8aAnop-j0qOfo9FN0eo6uyD699n0R_Q3q32Cu_OSDd1EnW4KxrvfR2VxW9f93-A3pvao-</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report</title><source>ScienceDirect Journals</source><source>PubMed Central</source><creator>Crowley, Fionnuala ; Fitzgerald, Bailey G. ; Bhardwaj, Aarti S. ; Siraj, Irine ; Smith, Cardinale</creator><creatorcontrib>Crowley, Fionnuala ; Fitzgerald, Bailey G. ; Bhardwaj, Aarti S. ; Siraj, Irine ; Smith, Cardinale</creatorcontrib><description>Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.</description><identifier>ISSN: 2666-3643</identifier><identifier>EISSN: 2666-3643</identifier><identifier>DOI: 10.1016/j.jtocrr.2021.100260</identifier><identifier>PMID: 35005653</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Case Report ; EGFR ; Myositis ; NSCLC ; Osimertinib</subject><ispartof>JTO clinical and research reports, 2022-01, Vol.3 (1), p.100260, Article 100260</ispartof><rights>2021 The Authors</rights><rights>2021 The Authors.</rights><rights>2021 The Authors 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-1c061e0747440198d5b8ac4ba3b2209905f8f18c0dbe8972c055aff933a9476a3</citedby><cites>FETCH-LOGICAL-c450t-1c061e0747440198d5b8ac4ba3b2209905f8f18c0dbe8972c055aff933a9476a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718495/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2666364321001193$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35005653$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crowley, Fionnuala</creatorcontrib><creatorcontrib>Fitzgerald, Bailey G.</creatorcontrib><creatorcontrib>Bhardwaj, Aarti S.</creatorcontrib><creatorcontrib>Siraj, Irine</creatorcontrib><creatorcontrib>Smith, Cardinale</creatorcontrib><title>Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report</title><title>JTO clinical and research reports</title><addtitle>JTO Clin Res Rep</addtitle><description>Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.</description><subject>Case Report</subject><subject>EGFR</subject><subject>Myositis</subject><subject>NSCLC</subject><subject>Osimertinib</subject><issn>2666-3643</issn><issn>2666-3643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kd1q3DAQhUVpaEKSNyhFL-Dt6NdyLwrF5A82TUlTArkRsizvyuxai6QE8vZV4jZNbnolMZrznRkdhD4SWBAg8vO4GHOwMS4oUFJKQCW8QwdUSlkxydn7V_d9dJzSCKVHEFIr-gHtMwEgpGAH6G7pB1fdrKMz2U1-WuHLx5B89gn7CRv8w2TvpoxvfV7jk7PT6-ryPpfWHn__2S5bHCZ8lfzWxewn333BrUkOX7tdiPkI7Q1mk9zxn_MQ_To9uWnPq-XV2UX7bVlZLiBXxIIkDmpecw6kUb3olLG8M6yjFJoGxKAGoiz0nVNNTS0IYYahYcw0vJaGHaKLmdsHM-pd9FsTH3UwXj8XQlxpU8azG6cZsNq4XikJgkOtGlBMEcuKp6WUscL6OrN2993W9basHs3mDfTty-TXehUetKqJ4o0oAD4DbAwpRTe8aAnop-j0qOfo9FN0eo6uyD699n0R_Q3q32Cu_OSDd1EnW4KxrvfR2VxW9f93-A3pvao-</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Crowley, Fionnuala</creator><creator>Fitzgerald, Bailey G.</creator><creator>Bhardwaj, Aarti S.</creator><creator>Siraj, Irine</creator><creator>Smith, Cardinale</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220101</creationdate><title>Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report</title><author>Crowley, Fionnuala ; Fitzgerald, Bailey G. ; Bhardwaj, Aarti S. ; Siraj, Irine ; Smith, Cardinale</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-1c061e0747440198d5b8ac4ba3b2209905f8f18c0dbe8972c055aff933a9476a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case Report</topic><topic>EGFR</topic><topic>Myositis</topic><topic>NSCLC</topic><topic>Osimertinib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crowley, Fionnuala</creatorcontrib><creatorcontrib>Fitzgerald, Bailey G.</creatorcontrib><creatorcontrib>Bhardwaj, Aarti S.</creatorcontrib><creatorcontrib>Siraj, Irine</creatorcontrib><creatorcontrib>Smith, Cardinale</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>JTO clinical and research reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crowley, Fionnuala</au><au>Fitzgerald, Bailey G.</au><au>Bhardwaj, Aarti S.</au><au>Siraj, Irine</au><au>Smith, Cardinale</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report</atitle><jtitle>JTO clinical and research reports</jtitle><addtitle>JTO Clin Res Rep</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>3</volume><issue>1</issue><spage>100260</spage><pages>100260-</pages><artnum>100260</artnum><issn>2666-3643</issn><eissn>2666-3643</eissn><abstract>Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35005653</pmid><doi>10.1016/j.jtocrr.2021.100260</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2666-3643
ispartof JTO clinical and research reports, 2022-01, Vol.3 (1), p.100260, Article 100260
issn 2666-3643
2666-3643
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3037aed886054078908381c3d5bc2233
source ScienceDirect Journals; PubMed Central
subjects Case Report
EGFR
Myositis
NSCLC
Osimertinib
title Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A05%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Life-Threatening%20Myositis%20in%20a%20Patient%20With%20EGFR-Mutated%20NSCLC%20on%20Osimertinib:%20Case%20Report&rft.jtitle=JTO%20clinical%20and%20research%20reports&rft.au=Crowley,%20Fionnuala&rft.date=2022-01-01&rft.volume=3&rft.issue=1&rft.spage=100260&rft.pages=100260-&rft.artnum=100260&rft.issn=2666-3643&rft.eissn=2666-3643&rft_id=info:doi/10.1016/j.jtocrr.2021.100260&rft_dat=%3Celsevier_doaj_%3ES2666364321001193%3C/elsevier_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-1c061e0747440198d5b8ac4ba3b2209905f8f18c0dbe8972c055aff933a9476a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/35005653&rfr_iscdi=true